Dose-Escalation Study of Cabozantinib in Combination With Lutetium-177 (177Lu)-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 14, 2023

Primary Completion Date

May 1, 2026

Study Completion Date

May 1, 2028

Conditions

Metastatic Castration-resistant Prostate Cancer

Interventions

DRUG

Cabozantinib

(177Lu)-PSMA-617 will be administered every 6 weeks for up to 6 cycles per SOC. Oral Cabozantinib taken daily at home.

Trial Locations (1)

RECRUITING

Huntsman Cancer Institute at University of Utah, Salt Lake City